NEWS & COMMENTS

PROHOST    FILTER

Top Stories Came from:

VERTEX (VRTX), GENZYME (GENZ), ONYX ONXX) and ALNYLAM  (ALNY). .

From Vertex: Outstanding data presented on Vertex’ anti-hepatitis protease inhibitor drug VX-950 at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna.

READ MORE: Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients

From Genzyme: The approval of Genzyme’s Pompe disease drug.

READ MORE: FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe Disease  

From Onyx: The recommendation for approval of Onyx/Bayer’s advanced kidney cancer drug Nexavar  

READ MORE: Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use

From Alnylam: The announcement of promising results of the firm’s RNAi drug, ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection.

READ MORE: Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection; Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting   

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm